Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

NCT05522738 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Combination: Fruquintinib + FOLFIRI

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]